Patents Assigned to ImClone Systems, Inc.
  • Antibody antagonists of VE-cadherin without adverse effects on vascular permeability
    Patent number: 7371574
    Abstract: The murine epitope sequence recognized by antibody E4B9 shares 100% homology with human VE-cadherin, so this antibody was examined to determine if it cross-reacts with human VIE-cadherin. Western-blot analysis of several VE-cadherin expressing human and murine ceH indicated that E4B9 indeed cross-reacts with human VE-cadherin (FIG. 6). This finding facilitates development of a “humanized” E4B9 antibody and its success in the prectinical development since its anti-tumor activity can be tested extensively in several mouse models.
    Type: Grant
    Filed: January 2, 2002
    Date of Patent: May 13, 2008
    Assignee: Imclone Systems, Inc.
    Inventors: Fang Liao, Daniel J. Hicklin, Peter Bohlen
  • Chimeric and humanized monoclonal antibodies specific to VEGF receptors
    Patent number: 6448077
    Abstract: Chimeric and humanized monoclonal antibodies that specifically bind to an extracellular domain of a VEGF receptor and neutralize activation of the receptor are provided. In vitro and in vivo methods of using these antibodies are also provided.
    Type: Grant
    Filed: November 10, 1997
    Date of Patent: September 10, 2002
    Assignee: ImClone Systems, Inc.
    Inventors: Patricia Rockwell, Neil I. Goldstein
  • Monoclonal antibodies specific to VEGF receptors and uses thereof
    Patent number: 6365157
    Abstract: Monoclonal antibodies that specifically bind to an extracellular domain of a flt-1 receptor and neutralize activation of the receptor are provided. In vitro and in vivo methods of using these antibodies are also provided.
    Type: Grant
    Filed: September 22, 1999
    Date of Patent: April 2, 2002
    Assignee: ImClone Systems, Inc.
    Inventors: Patricia Rockwell, Neil I. Goldstein